About Silence Therapeutics Silence Therapeutics is developing a new generation of medicines by harnessing the body s natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence s proprietary mRNAi GOLD™ platform can be used to create siRNAs that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence s wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address iron loading anemias. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Takeda, among others. For more information, please visit https://www.silence-therapeutics.com/.
Bicycle Therapeutics plc: Bicycle Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
BT7480, the lead Bicycle
tumor-targeted immune cell agonist, presented at AACR Annual Meeting 2021 New Drugs on the Horizon session; remains on-track for 2H 21 clinical trial start
Achieved significant recent progress across pipeline of Bicycle
-based therapies beyond oncology
Raised $75.0 million through at-the-market offering program; cash of $195.9 million as of March 31, 2021 expected to provide financial runway through multiple clinical milestones and into 2024
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (
Bicycle) technology, today reported financial results for the first quarter ended March 31, 2021 and discussed recent corporate updates.
Achilles Therapeutics PLC: Achilles Therapeutics Receives Horizon 2020 Grant as Part of Neoantigen Consortium
Research and Innovation program to develop a tool for the prediction of neoantigen immunogenicity
LONDON, May 06, 2021 (GLOBE NEWSWIRE) Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that it is a member of a consortium that has been awarded a grant from Horizon 2020, an EU Research and Innovation program. The consortium, which is led by UCL and includes The Francis Crick Institute, the Weizmann Institute of Science, and the Technical University of Denmark, in addition to Achilles, will research the immunogenicity of tumor neoantigens with the aim of developing a tool to predict neoantigen immunogenicity.
Achilles Therapeutics Receives Horizon 2020 Grant as Part of Neoantigen Consortium
Research and Innovation program to develop a tool for the prediction of neoantigen immunogenicity
LONDON, May 06, 2021 (GLOBE NEWSWIRE) Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that it is a member of a consortium that has been awarded a grant from Horizon 2020, an EU Research and Innovation program. The consortium, which is led by UCL and includes The Francis Crick Institute, the Weizmann Institute of Science, and the Technical University of Denmark, in addition to Achilles, will research the immunogenicity of tumor neoantigens with the aim of developing a tool to predict neoantigen immunogenicity.